Details of the Drug
General Information of Drug (ID: DMA106W)
| Drug Name |
Voacangine
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
Voacangine; CHEMBL182120; Carbomethoxyibogaine; (-)-Voacangine; 510-22-5; methyl ethyl(methoxy)[ ]carboxylate; AC1L2JJV; 12-Methoxyibogamine-18-carboxylic acid methyl ester; MMAYTCMMKJYIAM-RUGRQLENSA-N; BDBM50329104; ZINC100392804; Methyl (1S)-3,13-diaza-17-ethyl-7-methoxypentacyclo[13.3.1.0< 2,10> 4,9> 13,18> ]nonadeca-2(10),4,6,8-tetraenecarboxylate
|
||||||||||||||||||
| Indication |
|
||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 368.5 | |||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 3.5 | ||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 4 | ||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 4 | ||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||
| Drug-Molecule Activity Atlas (DMA)NEW | Click to Jump to the Detailed DMA Information of This Drug | ||||||||||||||||||
| Drug ADMET Endpoint Profile (DAE)NEW | Click to Jump to the Detailed DAE Information of This Drug | ||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||
|
||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||


